{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T06:22:07Z","timestamp":1788070927517,"version":"build-2784847793"},"reference-count":73,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"seventh framework programme for Research and Technological development of the EU"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nPreeclampsia causes substantial maternal and perinatal morbidity and mortality and significant societal economic impact. Effective screening would facilitate timely and appropriate prevention and management of preeclampsia.<\/jats:p>\n<\/jats:sec>\n\nObjectives<\/jats:title>\nTo develop an early cost-effectiveness analysis to assess both costs and health outcomes of a new screening test for preeclampsia from a healthcare payer perspective, in the United Kingdom (UK), Ireland, the Netherlands and Sweden.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nA decision tree over a 9-month time horizon was developed to explore the cost-effectiveness of the new screening test for preeclampsia compared to the current screening strategy. The new test strategy is being developed so that it can stratify healthy low risk nulliparous women early in pregnancy to either a high-risk group with a risk of 1 in 6 or more of developing preeclampsia, or a low-risk group with a risk of 1 in 100 or less. The model simulated 25 plausible scenarios in a hypothetical cohort of 100,000 pregnant women, in which the sensitivity and specificity of the new test were varied to set a benchmark for the minimum test performance that is needed for the test to become cost-effective. The input parameters and costs were mainly derived from published literature. The main outcome was incremental costs per preeclampsia case averted, expressed as an incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted to assess uncertainty.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nBase case results showed that the new test strategy would be more effective and less costly compared to the current situation in the UK. In the Netherlands, the majority of scenarios would be cost-effective from a threshold of \u20ac50,000 per preeclampsia case averted, while in Ireland and Sweden, the vast majority of scenarios would be considered cost-effective only when a threshold of \u20ac100,000 was used. In the best case analyses, ICERs were more favourable in all four participating countries. Aspirin effectiveness, prevalence of preeclampsia, accuracy of the new screening test and cost of regular antenatal care were identified as driving factors for the cost-effectiveness of screening for preeclampsia.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nThe results indicate that the new screening test for preeclampsia has potential to be cost-effective. Further studies based on proven accuracy of the test will confirm whether the new screening test is a cost-effective additional option to the current situation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0267313","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:33:19Z","timestamp":1650562399000},"page":"e0267313","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Early cost-effectiveness analysis of screening for preeclampsia in nulliparous women: A modelling approach in European high-income settings"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-5567","authenticated-orcid":true,"given":"Neily","family":"Zakiyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-7335","authenticated-orcid":true,"given":"Robin","family":"Tuytten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette D. I.","family":"van Asselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of IMPROvED Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"pone.0267313.ref001","article-title":"Reproductive, maternal, newborn, and child health: key messages from Disease Control Priorities 3rd Edition.","author":"RE Black","year":"2016","journal-title":"The Lancet"},{"key":"pone.0267313.ref002","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"L Say","year":"2014","journal-title":"The Lancet Global Health"},{"key":"pone.0267313.ref003","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(16)31527-6","article-title":"Drivers of maternity care in high-income countries: can health systems support woman-centred care?","volume":"388","author":"D Shaw","year":"2016","journal-title":"The Lancet"},{"key":"pone.0267313.ref004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/HYPERTENSIONAHA.114.03578","article-title":"Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study","volume":"64","author":"LC Kenny","year":"2014","journal-title":"Hypertension (Dallas, Tex: 1979)."},{"key":"pone.0267313.ref005","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/1471-0528.12309","article-title":"Does screening for pre-eclampsia make sense?","volume":"120","author":"C Hyde","year":"2013","journal-title":"BJOG: An International Journal of Obstetrics and Gynaecology"},{"key":"pone.0267313.ref006","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.AOG.0000437382.03963.88","article-title":"Hypertension in Pregnancy","volume":"122","author":"American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy","year":"2013","journal-title":"Obstetrics & Gynecology"},{"key":"pone.0267313.ref007","author":"National Institute for Clinical Excellence (NICE)","year":"2019","journal-title":"Hypertension in pregnancy: diagnosis and management"},{"key":"pone.0267313.ref008","author":"WHO","year":"2011"},{"key":"pone.0267313.ref009","doi-asserted-by":"crossref","first-page":"d1875","DOI":"10.1136\/bmj.d1875","article-title":"Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort","volume":"342","author":"RA North","year":"2011","journal-title":"BMJ"},{"key":"pone.0267313.ref010","first-page":"33","article-title":"Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments","author":"N Zakiyah","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"pone.0267313.ref011","article-title":"Cost effectiveness analysis of a model of first trimester prediction and prevention for preterm preeclampsia against usual care","author":"F P","year":"2020","journal-title":"Ultrasound Obstet Gynecol"},{"key":"pone.0267313.ref012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pd.2871","article-title":"Economic assessment of screening for pre-eclampsia","volume":"32","author":"A Shmueli","year":"2012","journal-title":"Prenat Diagn"},{"key":"pone.0267313.ref013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/uog.19076","article-title":"Cost-effectiveness of first-trimester screening with early preventative use of aspirin in women at high risk of early-onset pre-eclampsia","volume":"53","author":"D Ortved","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"pone.0267313.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta12060","article-title":"Methods of prediction and prevention of pre-eclampsia: Systematic reviews of accuracy and effectiveness literature with economic modelling","volume":"12","author":"C Meads","year":"2008","journal-title":"Health Technology Assessment"},{"key":"pone.0267313.ref015","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0000000000003413","article-title":"Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis.","volume":"134","author":"D M","year":"2019","journal-title":"Obstet Gynecol"},{"key":"pone.0267313.ref016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/cer-2018-0033","article-title":"Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies","volume":"8","author":"DI Ling","year":"2019","journal-title":"J Comp Eff Res"},{"key":"pone.0267313.ref017","unstructured":"IMproved Pregnancy Outcomes by Early Detection (IMPROvED). Personalised medicine for pregnant women: novel metabolomic and proteomic biomarkers to detect pre-eclampsia and improve outcome. Available: http:\/\/www.fp7-improved.eu\/"},{"key":"pone.0267313.ref018","first-page":"13","article-title":"A multi-centre phase IIa clinical study of predictive testing for preeclampsia: Improved pregnancy outcomes via early detection (IMPROvED)","author":"K Navaratnam","year":"2013","journal-title":"BMC Pregnancy and Childbirth"},{"key":"pone.0267313.ref019","doi-asserted-by":"crossref","first-page":"e0244369","DOI":"10.1371\/journal.pone.0244369","article-title":"Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test.","volume":"15","author":"LC Kenny","year":"2020","journal-title":"PLOS ONE"},{"key":"pone.0267313.ref020","author":"G Thomas","journal-title":"A novel method for interrogating receiver operating characteristic curves for assessing prognostic tests"},{"key":"pone.0267313.ref021","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"16","author":"D Husereau","journal-title":"Value Health"},{"key":"pone.0267313.ref022","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/HYPERTENSIONAHA.110.157297","article-title":"Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers","volume":"56","author":"LC Kenny","year":"2010","journal-title":"Hypertension (Dallas, Tex: 1979)."},{"key":"pone.0267313.ref023","article-title":"Hypertensive disorders of pregnancy and eclampsia","author":"Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)","year":"2015"},{"key":"pone.0267313.ref024","article-title":"Richtlijn Basis Prenatale zorg: opsporing van de belangrijkste zwangerschapscomplicaties bij laagrisico zwangeren (in de 2de en 3de lijn)","author":"Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG)","year":"2015"},{"key":"pone.0267313.ref025","article-title":"CLINICAL PRACTICE GUIDELINE, THE MANAGEMENT OF HYPERTENSION IN PREGNANCY","author":"Institute of Obstetricians and Gynaecologists Health Service Executive, Royal College of Physicians of Ireland & Clinical Strategy and Programmes Division","year":"2016"},{"key":"pone.0267313.ref026","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"pone.0267313.ref027","article-title":"Kvinnosjukdomar och f\u00f6rlossning, v\u00e5rdriktlinjer\u2014V\u00e5rdgivare Sk\u00e5ne","author":"Region Sk\u00e5ne","year":"2021"},{"key":"pone.0267313.ref028","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.annepidem.2014.10.003","article-title":"Risk factors differ between recurrent and incident preeclampsia: a hospital-based cohort study","volume":"24","author":"NS Boghossian","year":"2014","journal-title":"Annals of Epidemiology"},{"key":"pone.0267313.ref029","doi-asserted-by":"crossref","first-page":"b2255","DOI":"10.1136\/bmj.b2255","article-title":"Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study","volume":"338","author":"S Hern\u00e1ndez-D\u00edaz","year":"2009","journal-title":"BMJ"},{"key":"pone.0267313.ref030","author":"National Institute for Clinical Excellence","year":"2008"},{"key":"pone.0267313.ref031","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/M13-2844","article-title":"Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the US Preventive Services Task ForceAspirin for Prevention of Morbidity and Mortality From Preeclampsia","volume":"160","author":"JT Henderson","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"pone.0267313.ref032","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data","volume":"369","author":"LM Askie","year":"2007","journal-title":"The Lancet"},{"key":"pone.0267313.ref033","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis","volume":"116","author":"E Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"pone.0267313.ref034","article-title":"Antiplatelet agents for preventing pre\u2010eclampsia and its complications","author":"L Duley","year":"2007","journal-title":"The Cochrane Library"},{"key":"pone.0267313.ref035","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.","volume":"377","author":"DL Rolnik","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0267313.ref036","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/AOG.0000000000001115","article-title":"A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States","volume":"126","author":"EF Werner","year":"2015","journal-title":"Obstet Gynecol"},{"key":"pone.0267313.ref037","first-page":"110","volume-title":"American Journal of Obstetrics and Gynecology","author":"S Roberge","year":"2017"},{"key":"pone.0267313.ref038","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.ajog.2015.02.018","article-title":"Competing risks model in screening for preeclampsia by maternal characteristics and medical history","volume":"213","author":"D Wright","year":"2015","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"pone.0267313.ref039","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12884-016-1130-6","article-title":"Effect of planned place of birth on obstetric interventions and maternal outcomes among low-risk women: a cohort study in the Netherlands","volume":"16","author":"N Bolten","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"key":"pone.0267313.ref040","unstructured":"Perined. Perinatale Zorg in Nederland 2015. 2016. Available: https:\/\/assets.perined.nl\/docs\/980021f9-6364-4dc1-9147-d976d6f4af8c.pdf"},{"key":"pone.0267313.ref041","doi-asserted-by":"crossref","first-page":"e81959","DOI":"10.1371\/journal.pone.0081959","article-title":"Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in The Netherlands.","volume":"8","author":"JF von S auf Altenstadt","year":"2013","journal-title":"PLoS One"},{"key":"pone.0267313.ref042","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1001\/jama.2013.6295","article-title":"Maternal obesity and risk of preterm delivery","volume":"309","author":"S Cnattingius","year":"2013","journal-title":"Jama"},{"key":"pone.0267313.ref043","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(16)31575-6","article-title":"Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"H Wang","year":"2016","journal-title":"The Lancet"},{"key":"pone.0267313.ref044","unstructured":"Department of Health, Commercial Medicines Unit (CMU). Drugs and pharmaceutical electronic market information (eMit). 2016. Available: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit"},{"key":"pone.0267313.ref045","unstructured":"Zorginstituut Nederland. Medicijnkosten. 2017. Available: https:\/\/www.medicijnkosten.nl\/"},{"key":"pone.0267313.ref046","article-title":"Estimating the Cost of Preeclampsia in the Healthcare System: Cross-Sectional Study Using Data From SCOPE Study (Screening for Pregnancy End Points).","author":"A Fox","year":"2017","journal-title":"Hypertension"},{"key":"pone.0267313.ref047","volume-title":"NHS Reference Costs 2017\u201318","author":"National Health Service (NHS)","year":"2020"},{"key":"pone.0267313.ref048","article-title":"The Royal Dutch Organisation of Midwives.","author":"Koninklijke Nederlandse Organisatie van Verloskundigen (KNOV)","year":"2020","journal-title":"Tarieven 2020"},{"key":"pone.0267313.ref049","year":"2017","journal-title":"S\u00f6dra Regionv\u00e5rdsn\u00e4mnden. Regionala priser och ers\u00e4ttningar f\u00f6r S\u00f6dra sjukv\u00e5rdsregionen"},{"key":"pone.0267313.ref050","author":"L Hakkaart-van Roijen","year":"2015","journal-title":"Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorgIn opdracht van Zorginstituut NederlandGeactualiseerde versie"},{"key":"pone.0267313.ref051","unstructured":"Fawsitt C. Valuing maternity care: a comparison of stated preference methods with an application to cost-benefit analysis. PhD Thesis, University College Cork, Ireland. 2015."},{"key":"pone.0267313.ref052","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1471-0528.2008.01935.x","article-title":"The long\u2010term cost\u2010effectiveness of fetal monitoring during labour: a comparison of cardiotocography complemented with ST analysis versus cardiotocography alone.","volume":"115","author":"E Heintz","year":"2008","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"key":"pone.0267313.ref053","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1472-6963-9-211","article-title":"Cost Analysis of the Dutch Obstetric System: low-risk nulliparous women preferring home or short-stay hospital birth-a prospective non-randomised controlled study","volume":"9","author":"MJC Hendrix","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"pone.0267313.ref054","unstructured":"Nederlandse Zorgautoriteit, Open DIS Data. Open DIS data. 2020. Available: http:\/\/www.opendisdata.nl\/"},{"key":"pone.0267313.ref055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00125-015-3824-0","article-title":"The cost-effectiveness of screening for gestational diabetes mellitus in primary and secondary care in the Republic of Ireland","volume":"59","author":"A Danyliv","year":"2016","journal-title":"Diabetologia"},{"key":"pone.0267313.ref056","volume-title":"Cochrane Database of Systematic Reviews","author":"L Duley","year":"2019"},{"key":"pone.0267313.ref057","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-0036-1572495","article-title":"Low-Dose Aspirin in Early Gestation for Prevention of Preeclampsia and Small-for-Gestational-Age Neonates: Meta-analysis of Large Randomized Trials.","volume":"33","author":"S Roberge","year":"2016","journal-title":"American Journal of Perinatology"},{"key":"pone.0267313.ref058","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1471-0528.1997.tb11497.x","article-title":"A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation","volume":"104","author":"H Leitich","year":"1997","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"pone.0267313.ref059","volume-title":"Cochrane Database of Systematic Reviews","author":"L Duley","year":"2007"},{"key":"pone.0267313.ref060","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.ajog.2015.08.042","article-title":"Why is placentation abnormal in preeclampsia?","volume":"213","author":"SJ Fisher","year":"2015","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"pone.0267313.ref061","first-page":"641","article-title":"Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia","volume":"39","year":"2011","journal-title":"J Perinat Med"},{"key":"pone.0267313.ref062","first-page":"8","article-title":"T rial of feasibility and acceptability of routine low-dose aspirin versus E arly S creening T est indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial","author":"F M","year":"2018","journal-title":"BMJ Open"},{"key":"pone.0267313.ref063","first-page":"498","article-title":"Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion","volume":"25","author":"E Soto","year":"2012"},{"key":"pone.0267313.ref064","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"MA Brown","year":"2018","journal-title":"Pregnancy Hypertension"},{"key":"pone.0267313.ref065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation","volume":"52","author":"MY T","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"pone.0267313.ref066","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2393-14-13","article-title":"Private health care coverage and increased risk of obstetric intervention.","volume":"14","author":"JE Lutomski","year":"2014","journal-title":"BMC Pregnancy and Childbirth"},{"key":"pone.0267313.ref067","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3111\/13696998.2010.535285","article-title":"Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective","volume":"13","author":"N Hadker","year":"2010","journal-title":"Journal of Medical Economics"},{"key":"pone.0267313.ref068","doi-asserted-by":"crossref","first-page":"685.e1","DOI":"10.1016\/j.ajog.2017.08.110","article-title":"Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia","volume":"217","author":"D W","year":"2017","journal-title":"Am J Obstet Gynecol."},{"key":"pone.0267313.ref069","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE trial: performance of screening for preterm pre-eclampsia","volume":"50","author":"DL Rolnik","year":"2017","journal-title":"Ultrasound in Obstetrics & Gynecology"},{"key":"pone.0267313.ref070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1017\/S0266462316000064","article-title":"The early bird catches the worm: early cost-effectiveness analysis of new medical tests","volume":"32","author":"LR Buisman","year":"2016","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"pone.0267313.ref071","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1057\/palgrave.jcb.3050062","article-title":"Investing in new medical technologies: A decision framework","volume":"13","author":"E Cosh","year":"2007","journal-title":"Journal of Commercial Biotechnology"},{"key":"pone.0267313.ref072","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.ajog.2013.12.001","article-title":"The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications","volume":"210","author":"MC Cusimano","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"pone.0267313.ref073","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ahj.2008.06.042","article-title":"Cardiovascular sequelae of preeclampsia\/eclampsia: A systematic review and meta-analyses","volume":"156","author":"SD McDonald","year":"2008","journal-title":"American Heart Journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T17:34:06Z","timestamp":1650562446000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267313"}},"subtitle":[],"editor":[{"given":"Pal Bela","family":"Szecsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267313","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}